指南与共识炎症性肠病消化内镜

AGA临床实践指南:生物标志物在溃疡性结肠炎管理中的作用

AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis.
指南 / 共识 · Gastroenterology · 2023-01-01

美国胃肠病协会(AGA)发布指南,采用GRADE框架评估血清C反应蛋白、粪便钙卫蛋白和粪便乳铁蛋白在溃疡性结肠炎疾病活动监测中的价值,提出7条条件性推荐,建议根据症状和生物标志物组合决定是否行内镜评估。

要点

  • 症状缓解期患者建议采用生物标志物联合症状的监测策略,优于仅基于症状的监测策略。
  • 症状缓解期可用粪便钙卫蛋白<150 μg/g、粪便乳铁蛋白正常和/或C反应蛋白正常排除活动性炎症,避免常规内镜评估。
  • 中重度症状患者建议用粪便钙卫蛋白>150 μg/g、粪便乳铁蛋白升高或C反应蛋白升高辅助治疗决策,避免常规内镜评估。

核心结论

  • 在溃疡性结肠炎患者中,粪便钙卫蛋白、粪便乳铁蛋白和血清C反应蛋白等无创生物标志物可辅助疾病监测和管理。

研究设计与样本

  • 美国胃肠病协会(AGA)指南,由多学科专家组和指南方法学家采用GRADE框架制定,聚焦已确诊溃疡性结肠炎患者。

主要发现

  • 指南专家组共提出7条条件性推荐。
  • 症状缓解期患者,建议采用生物标志物联合症状的监测策略,优于仅基于症状的监测策略。
  • 症状缓解期患者,建议使用粪便钙卫蛋白<150 μg/g、粪便乳铁蛋白正常和/或C反应蛋白正常排除活动性炎症,避免常规内镜评估。
  • 中重度症状患者,建议使用粪便钙卫蛋白>150 μg/g、粪便乳铁蛋白升高或C反应蛋白升高辅助治疗决策,避免常规内镜评估。

关键数值与推荐

  • 症状缓解期患者:建议采用生物标志物联合症状的监测策略优于仅基于症状的监测策略(条件性推荐)。
  • 症状缓解期患者:建议粪便钙卫蛋白<150 μg/g、粪便乳铁蛋白正常和/或C反应蛋白正常用于排除活动性炎症并避免常规内镜评估(条件性推荐)。
  • 中重度症状患者:建议粪便钙卫蛋白>150 μg/g、粪便乳铁蛋白升高或C反应蛋白升高用于辅助治疗决策并避免常规内镜评估(条件性推荐)。
  • 症状缓解期但生物标志物升高、或中重度症状但生物标志物正常的患者:建议行内镜评估以指导治疗决策(条件性推荐)。
  • 轻度症状患者:建议行内镜评估疾病活动度以指导治疗决策(条件性推荐)。

临床怎么用

  • 症状缓解期患者可采用生物标志物联合症状的监测策略,减少不必要的内镜评估。
  • 中重度症状患者可依据粪便钙卫蛋白>150 μg/g、粪便乳铁蛋白升高或C反应蛋白升高启动治疗决策,避免常规内镜。
  • 症状缓解但生物标志物升高,或中重度症状但生物标志物正常时,应行内镜评估。
  • 轻度症状患者建议行内镜评估疾病活动度以指导治疗。

局限性

  • 专家组将生物标志物监测策略优于内镜监测策略列为知识空白。
  • 专家组确定了未来研究的方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Biomarkers are used frequently for noninvasive monitoring and treatment decision making in the management of patients with ulcerative colitis (UC). This American Gastroenterological Association (AGA) guideline is intended to support practitioners in decisions about the use of biomarkers for the management of UC. METHODS: A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation framework to prioritize clinical questions, identify patient-centered outcomes, and conduct an evidence synthesis on the clinical performance of serum C-reactive protein (CRP), fecal calprotectin, and fecal lactoferrin as biomarkers of disease activity in patients with established UC in symptomatic remission or with active symptoms. The guideline panel used the Evidence-to-Decision framework to develop recommendations for the use of biomarkers for monitoring and management of UC and provided implementation considerations for clinical practice. RESULTS: The guideline panel made 7 conditional recommendations. In patients with UC in symptomatic remission, the panel suggests the use of a biomarker- and symptom-based monitoring strategy over a symptom-based monitoring strategy. For patients in symptomatic remission, the panel suggests using fecal calprotectin <150 μg/g, normal fecal lactoferrin, and/or normal CRP to rule out active inflammation and avoid routine endoscopic assessment of disease. In patients with UC with moderate to severe symptoms, the panel suggests using fecal calprotectin >150 μg/g, elevated fecal lactoferrin, or elevated CRP to inform treatment decisions and avoid routine endoscopic assessment of disease. However, in patients in symptomatic remission but elevated biomarkers, and in patients with moderate to severe symptoms with normal biomarkers, the panel suggests endoscopic assessment of disease to inform treatment decisions. In patients with UC with mild symptoms, the panel suggests endoscopic assessment of disease activity to inform treatment decisions. The panel identified the use of a biomarker-based monitoring strategy over an endoscopy-based monitoring strategy as a knowledge gap. The panel also proposed key implementation considerations for optimal use of biomarkers, and identified areas for future research. CONCLUSIONS: In patients with UC, noninvasive biomarkers, including fecal calprotectin, fecal lactoferrin, and serum CRP can inform disease monitoring and management.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Singh S, Ananthakrishnan AN, Nguyen NH, et al. AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. Gastroenterology. 2023. PMID: 36822736. doi:10.1053/j.gastro.2022.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。